80 likes | 658 Views
OPIM 5894 Advanced Project management Vertex Pharmaceuticals case. TEAM 1. http://users.business.uconn.edu/snair/opim5894.html. Vertex Pharmaceuticals case. Which of the 4 project portfolio options currently facing Vertex do you favor? VX-765 Big money Earliest in development
E N D
OPIM 5894 Advanced Project managementVertex Pharmaceuticals case TEAM 1 http://users.business.uconn.edu/snair/opim5894.html
Vertex Pharmaceuticals case • Which of the 4 project portfolio options currently facing Vertex do you favor? VX-765 • Big money • Earliest in development • Biggest risk Prof. Suresh Nair, University of Connecticut
Vertex Pharmaceuticals case • Specifically, which two projects would you advance in development? Why? Show analysis. VX-702, VX-765 • Highest expected values • See graphs Prof. Suresh Nair, University of Connecticut
Vertex Pharmaceuticals case Prof. Suresh Nair, University of Connecticut
Vertex Pharmaceuticals case • Would you license out the two others not chosen or keep them as backup? • VX-148 – license out • VX-950 – license out • How much should Vertex management rely on quantitative methodologies (such as real option valuation) versus more qualitative approaches? • Quantitative Methodologies – 75% • Qualitative Approaches – 25% Prof. Suresh Nair, University of Connecticut
Revenue Stream Prof. Suresh Nair, University of Connecticut